Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anjianning (adalimumab) in moderately to severely active Crohn's disease – real-world multicenter single-arm study
ChiCTR2500106175Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anjianning in Crohn's disease, sponsored by Tangdu Hospital. Primary endpoints: Proportion of CD patients achieving clinical remission and clinical response and Proportion of subjects who discontinue corticosteroids and achieve clinical remission. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
anjianning
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500106175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106175.